BACKGROUND: To investigate the anesthetic management in premature infants with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB) injections. METHODS: A retrospective chart review was performed for the patients with ROP who had IVB injection. Clinical characteristics, demographic variables, anesthetic medications, operation techniques, time intervals, and complications were recorded. RESULTS: Sixty-six eyes of 33 patients (23 males, 10 females) with type 1 ROP who were treated with IVB were included. A total of 66 anesthetic applications were performed. Mean gestational age at birth was 28.3 weeks (range 25-33). Mean birth weight was 1,300 g (range 600-1850). Serious ocular and systemic complications were not observed in any infant. CONCLUSION: Inhalation anesthesia with sevoflurane during IVB treatment in premature infants with ROP may be appropriate for anesthetic management.
BACKGROUND: To investigate the anesthetic management in premature infants with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB) injections. METHODS: A retrospective chart review was performed for the patients with ROP who had IVB injection. Clinical characteristics, demographic variables, anesthetic medications, operation techniques, time intervals, and complications were recorded. RESULTS: Sixty-six eyes of 33 patients (23 males, 10 females) with type 1 ROP who were treated with IVB were included. A total of 66 anesthetic applications were performed. Mean gestational age at birth was 28.3 weeks (range 25-33). Mean birth weight was 1,300 g (range 600-1850). Serious ocular and systemic complications were not observed in any infant. CONCLUSION: Inhalation anesthesia with sevoflurane during IVB treatment in premature infants with ROP may be appropriate for anesthetic management.
Authors: Virginia A Marsh; William O Young; Kimberly K Dunaway; Grace E Kissling; Rita Q Carlos; Susan M Jones; Dawn H Shockley; Nicole L Weaver; J Laurence Ransom; Peter Gal Journal: Ann Pharmacother Date: 2005-03-29 Impact factor: 3.154
Authors: Hugo Quiroz-Mercado; Maria A Martinez-Castellanos; Myriam L Hernandez-Rojas; Nelida Salazar-Teran; Robinson Vernon Paul Chan Journal: Retina Date: 2008-03 Impact factor: 4.256